Plant-Based Vaccines Market Analysis & Forecast: 2026-2033

Plant-Based Vaccines Market is estimated to be valued at USD 332.8 Mn in 2026 and is expected to reach USD 6,097.2 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 51.5% from 2026 to 2033.

Analysts’ Views on the Global Plant-based Vaccines Market:

The increasing research and development of plant-based vaccines is expected to drive the growth of the market over the forecast period. For instance, according to data published in September 2021 by Genetic Engineering & Biotechnology News University of California-Riverside, researchers are studying whether it can turn edible plants like lettuce into mRNA vaccine factories.

Figure 1. Global Plant-based Vaccines Market Share (%), By Application, 2026

To learn more about this report, Download Free Sample

Global Plant-based Vaccines Market - Drivers

• Increasing research and development activities: Increasing research and development activities are expected to drive the growth of the global plant-based vaccines market over the forecast period. The study is currently in phase 2. The study is estimated to be completed in April 2026.

Figure 2. Global Plant-based Vaccines Market Share (%), By Region, 2026

To learn more about this report, Download Free Sample

Global Plant-based Vaccines Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global plant-based vaccines market over the forecast period. The global plant-based vaccines market is expected to witness significant growth in the coming years, driven by the increasing technology advancement of plant based vaccines.

• In many countries, hospitals and ICU departments are overloaded or on the verge of a potential collapse. Therefore, optimal allocation of healthcare resources is required. Healthcare professionals are forced to treat severely ill patients with limited access to ventilation equipment, qualified intensive care personnel, or protective patient monitoring devices.

Global Plant-based Vaccines Market Segmentation:

The global plant-based vaccines market report is segmented into vaccine type, source, application and region.

• By vaccine type, the market is segmented into bacterial vaccines, viral vaccines, parasite vaccines and others. Out of which, the bacterial vaccine segment is expected to hold a dominant position in the global plant-based vaccines market during the forecast period. Bacterial vaccines contain killed or attenuated bacteria that activate the immune system. Antibodies are built against that particular bacteria, and prevents bacterial infection later.
• By application,ebolavirus, poultry disease, and others. For instance, in February 2022, Medicago AB, a biopharmaceutical company, announced that Health Canada had granted approval for the COVIFENZ,, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
• By source, the market is segmented into tobacco plant, maize, potato, and others. Out of which, tobacco plant is expected to dominate the market over the forecast period, and this is attributed to the increasing launch of new companies. For instance, in January 2022, British American Tobacco (BAT), a multi-category consumer goods company that provides tobacco and nicotine products, launched Kentucky BioProcessing (KBP), a wholly owned subsidiary of British American Tobacco (BAT). The new company will focus on using tobacco plants to develop biologics and vaccines for rare and infectious diseases.

Global Plant-based Vaccines Market - Cross Sectional Analysis:

Increasing prevalence of the Ebola Virus in Africa is expected to drive the growth of the Africa market over the forecast period. For instance, according to data published in December 2021 by the National Library of Medicine, in 2020, 3470 Ebola virus disease cases had been reported, including 3317 confirmed and 153 probable cases, with 2287 deaths in the Democratic Republic of the Congo, Africa.

Global Plant-based Vaccines Market: Key Developments

• On September 24, 2020, Lumen Bioscience, Inc.,a pharmaceutical company, received US$ 4 million grant from Series B financing round from the investors such as WestRiver Management, Bioeconomy Capital, and others.
• In June 2022, Mazen Animal Health, a biotechnology company, announced that the company is getting closer to completing the development of a novel vaccine that would be produced in corn and administered through animal feed.

Global Plant-based Vaccines Market: Key Trends

• Increasing funding by the government: Increasing funding by the government for the development of plant-based vaccines is expected to drive the growth of the global plant-based vaccines market over the forecast period. For instance, according to data published in May 2022 by HT Digital Streams Ltd, an online news company, the Canadian government provided US$173 million in funding to Medicago Inc., a biotechnology company, for its development of Covifenz, the world’s first plant-based COVID vaccine.

Global Plant-based Vaccines Market: Restraint

• Disadvantages and potential risk of contamination and environmental risks: Disadvantages and potential risks of contamination and environmental risks are expected to hinder the growth of the global plant-based vaccines market in the near future. Pollen contamination difficulties with field crop-based Plant Molecular Farming (PMF) platforms, such as platforms based on maize or rice, create biosafety concerns as pollen may contaminate non-transgenic crops that are part of standard agricultural production. Currently, the U.S. FDA has a restricted policy for using food crops for the production of recombinant pharmaceutical compounds.

 Global Plant-based Vaccines Market - Key Players

The major players operating in the global plant-based vaccines market include Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI).

Definition: Plant-derived vaccines are produced by recombinant technology, in which the gene encoding the desired antigen protein is integrated into the plant genome. Agrobacterium tumefaciens is commonly used for gene transfer and transformation.